|drug2500||Pilot a rapid SARS-CoV-2 testing strategy Wiki||1.00|
|drug3660||Virtual Care at Home Wiki||1.00|
There is one clinical trial.
The purpose of this study is to assess the feasibility of establishing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) testing at a federally-qualified health center (FQHC) during a global health crisis to mitigate COVID-19 disparities in socioeconomically disadvantaged populations.
Description: FQHC staff will complete a comprehensive electronic survey adapted from the Acceptability of Intervention Measure (AIM), Intervention Appropriateness Measure (IAM), and Feasibility of Intervention Measure (FIM) instrument to assess feasibility of community-engaged research partnership to support testing site (Weiner BJ, et al. Implementation Science. 2017;12(1):108.).Measure: Intervention Feasibility Measures - FQHC Staff Time: 6-months after intervention start
Description: Comparison of number of tests completed per group (intervention vs. control)Measure: 2. Uptake of rapid SARS-CoV-2 testing strategy at the FQHC- Effectiveness of community-driven messaging to patients Time: 6-months after intervention start
Description: Comparison of number of tests completed per group (intervention vs. control)Measure: Uptake of rapid SARS-CoV-2 testing strategy at the FQHC Time: 9-months after intervention start
Description: All randomized patients will complete a comprehensive survey with questions probing satisfaction with the drive-through testing site (ease of use, process, return of results, etc.).Measure: Intervention Satisfaction Measures - Participant Satisfaction with COVID-19 testing Time: 6-months after intervention start
Description: Compare the satisfaction of community-driven messaging on availability of rapid SARS-CoV-2 testing at the FQHC (intervention vs. control)Measure: 5. Intervention Satisfaction Measures - Participant Satisfaction with community-driven messaging Time: 6-months after intervention start
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports